Surgery Godfather Chapter 1873: 1301: Professor, I've Uncovered Another Secret

Capítulo 1873: Chapter 1301: Professor, I’ve Uncovered Another Secret (Part 2)

“This ans, Mr. Shen will beco our first late-stage pancreatic cancer patient under long-term managent,” Dr. Li said. “His treatnt will not have a definite end date; it may last for years, possibly for life, or it may even be cured by next month.”

Shen Guohua and Zhou Min understood. There is no cure, only control—like hypertension or diabetes—living long-term with cancer.

“As long as I live,” Shen Guohua said simply, holding his wife’s hand tightly.

From the despair of diagnosis to the thrills of treatnt, and now living with the disease, this is the best outco.

Any late-stage malignant tumor patient would jump for joy if they heard they could live with the disease and control it for life, just like with hypertension or diabetes.

Yang Ping pondered why K therapy could cure osteosarcoma but not pancreatic cancer. It’s because the K Factor is inherently designed for osteosarcoma. Whether through targeting or triggering programs, osteosarcoma cells have no way to counter; no matter how they evade, they can’t escape being hunted. However, the K Factor doesn’t work for pancreatic cancer due to the lack of specific stable targets, relying only on general targets that are subject to change at any ti.

…

Ruixing Company eting Room.

Huang Jiacai spread out two reports in front of him, one from the market intelligence departnt, detailing the activities in the first month since Wu Changde’s open platform went live: 43 dostic and international research institutions have registered to use the “Keystones” module; eight “collaborative research projects” have been initiated on the platform.

A mid-size biopharmaceutical company in East China announced that, based on the platform module, they completed the simulation construction of a CAR-T vector targeting a lung cancer target in just eight weeks and initiated experintal research.

Wu Changde’s team published two consecutive papers in the top academic journal “Nature Biotechnology,” explaining their modular design concept and preliminary validation data, with a soaring citation rate.

There are rumors that Wu Changde is in contact with a well-known international open-source software foundation, hoping to internationalize the platform’s “open source” governance model.

The report concludes: The open platform is rapidly gaining popularity, resources, and reputation, with its ecological effects beginning to appear.

Regarding Wu Changde’s research, Dr. Walker, a forr senior scientist at BG Group, privately expressed significant concerns, stating that Wu Changde underestimates the technical content of K therapy, noting that Wu Changde doesn’t fully understand this technology. All current investnts are wasting resources and may eventually trigger a series of serious problems. It’s not possible to even replicate the original technology without several years.

Another report cos from Ruixing’s own R&D and clinical team:

Total global cases treated with K therapy have surpassed 500 (including clinical trials and compassionate use), with an overall objective response rate of 78%, and a complete response rate of 22%.

The new dual-target vector process is becoming stable, with GMP production line modifications 60% complete.

The “mixed vector library” strategy addressing adenovirus pre-existing immunity issues has shown value in European compassionate use cases, successfully matching effective vectors for 17 antibody-positive patients.

The long-term maintenance managent model derived from Shen Guohua’s case is forming a standardized frawork, which is undoubtedly another innovation. Before the ultimate therapy erges, it ensures patient survival rates.

…

The Frankfurt Mirror Center construction is complete, entering the final sprint phase for equipnt debugging and European Union safety certification.

The report also lists problems and challenges: Treatnt costs remain high. Despite the availability-frawork tiered pricing, the full cost of a single treatnt still exceeds 500,000 RMB, and negotiations for dical insurance coverage progress slowly worldwide.

International dical teams, such as Carlos, Rajiv, and others, report all sorts of practical issues, from cold chain logistics interruptions to conflicts with local dical regulations, consuming significant support resources.

Zurich, European Commission Health Departnt internal briefing eting.

Carl Schmidt is reporting to the high-level executives on the implentation of the K therapy “compassionate use” plan in its first month.

“As of yesterday, a total of 41 compassionate use applications have been approved across the European Union (including Switzerland, Norway, and other associated countries), involving eight solid tumors such as pancreatic cancer, bile duct cancer, and glioblastoma. Treatnt has been completed for 22 cases.”

“Early data shows: objective response rate (ORR) is 81.82%. In terms of safety, the incidence of Grade 3 or higher adverse reactions is 4.55%, mainly controllable cytokine release syndro and transient liver function impairnt, with no treatnt-related deaths.”

“Through the Frankfurt Mirror Center, data passage runs smoothly, and the joint oversight committee has convened three etings, conducting a review of one suspected unexpected serious adverse event, determining it to be related to disease progression rather than requiring plan discontinuation.”

“Patient organizations and dia feedback are generally positive, seeing this as a good balance between regulatory flexibility and the protection of patient rights.”

“However,” Carl’s tone shifted, “we also observe so challenges. First, treatnt costs are high. Even with Ruixing covering part of the monitoring costs, most expenses still need to be borne by national dical insurance or out-of-pocket by patients, highlighting fairness issues. Second, so mber states express concern over the expansion of compassionate use, fearing it may undermine the authority of formal approval processes and indirectly encourage dical tourism. Finally, Ruixing’s proposed outco-sharing insurance model faces complicated insurance regulatory obstacles in Europe.”